Which Factors Enhance Positive Drug Reimbursement Recommendation in Scotland?:A retrospective analysis 2006-2013 by Charokopou, Mata et al.
  
 University of Groningen
Which Factors Enhance Positive Drug Reimbursement Recommendation in Scotland?






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Charokopou, M., Majer, I. M., Raad, J. D., Broekhuizen, S., Postma, M., & Heeg, B. (2015). Which Factors
Enhance Positive Drug Reimbursement Recommendation in Scotland? A retrospective analysis 2006-
2013. Value in Health, 18(2), 284-291. https://doi.org/10.1016/j.jval.2014.12.008
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019




* Address correspojournal homepage: www.elsevier .com/ locate / jva lWhich Factors Enhance Positive Drug Reimbursement
Recommendation in Scotland? A Retrospective
Analysis 2006–2013
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Stefan Broekhuizen, BSc1, Maarten Postma, PhD2, Bart Heeg, MSc1
1Pharmerit BV, Rotterdam, The Netherlands; 2Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy,
University of Groningen, Groningen, The NetherlandsA B S T R A C TObjectives: To identify the factors that inﬂuence the Scottish Med-
icines Consortium (SMC) in deciding whether to accept pharma-
ceutical technologies for use within the Scottish health care system.
Methods: A database of SMC submissions between 2006 and 2013
was created, containing a range of clinical, economic, and other
factors extracted from published health technology assessment
reports. A binomial outcome variable was used, deﬁned as the
decision to “accept for use” or “not recommend” a technology.
Univariate and multivariate analyses were conducted to assess the
impact by means of odds ratios (ORs) of the submitted evidence on
the recommendation decision. Results: Out of 463 applications, 265
were accepted for use (57%) and 198 (43%) were not recommended
for use within National Health Service Scotland. Univariate analyses
showed that 13 variables signiﬁcantly affected the SMC decision. Of
these 13 variables, 7 variables were shown to have a meaningful
impact in the multivariate analysis. Four of these concerned the




ndence to: Mata Charokopou, Marten Meesweg 10was supported by a cost-minimization analysis was the strongest
positive variable (OR ¼ 10.30) and a submission showing a product
not being cost-effective (i.e., incremental cost-effectiveness ratio
above £30,000/quality-adjusted life-year gained) was the strongest
negative predictor (OR ¼ 0.47). The other variables concerned
whether the submission was related to a product indicated for a
nervous system disease (OR ¼ 0.41), whether it was indicated for
nonchronic use (OR ¼ 1.66), and whether the submission was
performed by a big company (OR ¼ 2.83). Conclusions: This study
demonstrated that the outcome of cost-effectiveness analyses is an
important factor affecting the SMC’s reimbursement recommenda-
tion decision.
Keywords: decision making, health technology assessment,
reimbursement, Scotland.
& 2015 Published by Elsevier Inc. on behalf of International Society for
Pharmacoeconomics and Outcomes Research (ISPOR).Introduction
Given limited health care resources and rising expenditures on
pharmaceuticals, policymakers are increasingly confronted with
the challenging task to improve patient outcomes and reimburse
new pharmaceutical interventions [1]. In several countries,
including England and Wales, Scotland, The Netherlands, Bel-
gium, Canada, Australia, and Sweden, health technology assess-
ment bodies have been set up to advise on whether health care
interventions should be recommended for public reimbursement
[2–4]. Most health technology assessment bodies consider evi-
dence not only on clinical effectiveness and safety but also on
various other factors such as cost-effectiveness and budgetary
impact. With more and more national health authorities request-
ing health economic evaluation for their reimbursement deci-
sions, the signiﬁcance of economic factors in the advisory or
decision-making process has increased.The importance of individual components of evidence, for
example, clinical outcomes, disease characteristics, and health
economic outcomes, which are submitted to local health author-
ities as part of a reimbursement dossier, however, is generally
not described. There is an exception for the National Institute for
Health and Care Excellence (NICE) in England and Wales, which
uses the incremental cost-effectiveness ratio (ICER) threshold of
£20,000 to £30,000 per quality-adjusted life-years (QALYs) gained.
Yet, NICE appraisals suggest that various factors are taken into
account and a drug can be positively assessed even if the ICER
exceeds that threshold. More precisely, as the ICER of an inter-
vention increases in the range of £20,000 to £30,000 per QALY
gained, the NICE Committee’s judgment about the acceptability
of the technology as an effective use of National Health Service
(NHS) resources will speciﬁcally take account of other factors,
such as the degree of certainty around the ICER, innovative
nature of the technology, inadequately captured quality-of-lifeon behalf of International Society for Pharmacoeconomics and
7, 3068 AV, Rotterdam, The Netherlands.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 8 4 – 2 9 1 285beneﬁts, and potential “life-extensive” nature of the treatment
under assessment [5]. Nevertheless, most countries have not set
a formal cost-effectiveness threshold for reimbursement; there-
fore, it is not clear how the economic results relate to other
factors in the decision or advisory process.
A number of quantitative studies have been previously con-
ducted to investigate what factors are inﬂuential and how much
impact these factors have on reimbursement decisions in speciﬁc
countries, including England and Wales [6–10], The Netherlands
[11], and Australia [12,13]. To our knowledge, no study has been
conducted for the Scottish Medicines Consortium (SMC).
Within the National Health Service for Scotland (NHS Scot-
land), 14 geographically based local NHS boards and a number of
National Special Health Boards are responsible for the provision
of health care [14]. The SMC, a consortium of NHS Scotland, was
established to beneﬁt patients by providing NHS boards and their
Area Drug and Therapeutics Committees with a single source of
advice about the value of each new medicine and the patients for
whom it would be most beneﬁcial [14,15]. In particular, the SMC
advises NHS Scotland whether a newly licensed drug should be
reimbursed on the basis of the value for money it represents to
NHS Scotland. The SMC provides a central reimbursement rec-
ommendation as soon as possible after the launch of the product,
which is based on the clinical and economic evidence provided by
the manufacturer [15,16]. The advisory process involves the
assessment of both clinical and economic evidence as submitted
by the manufacturer by lead clinicians, pharmacists, and health
economists together with representatives of health boards, the
pharmaceutical industry, and patient associations [15,16]. The
SMC can positively assess and accept a drug for either routine or
restricted use, or, alternatively, it can suggest rejection of public
funding of the medicine [16]. On completion of the SMC assess-
ment process, its advice for NHS Scotland is published and the
ﬁnal formulary inclusion decision is made by the local health
boards using this advice. It is important to note that NHS boards
will consider all SMC-accepted advice as a matter of course but
can still decide not to include such medicines on their own local
formulary, that is, where the medicine does not represent
sufﬁcient added beneﬁt to other medicines already on the
formulary for the same indication [15]. Detailed information is
available on the organization’s Web site (www.scottishmedicines
consortium.com) [15].
Arguably, Scotland is often one of the ﬁrst European countries
where manufacturers ﬁle a submission dossier requesting public
reimbursement for their product. Manufacturers submit their
evidence to the SMC before they submit it to the relevant health
technology assessment body of England and Wales, NICE [14,17].
It seems that SMC’s assessment of evidence approach is closer to
that used elsewhere in Europe and its activities are to a large
extent complementary to the ones of NICE [14,18]. The SMC
advisory process is transparent in the sense that all decisions
and argumentations are published on SMC’s Web site since 2002
[15]. Hence, feedback of the SMC on a submission might have
implications on decisions of other health authorities and affect
the product’s pricing in Europe on grounds of the reference
pricing system [19].
The purpose of the present study was to investigate the
weight that different pieces of evidence, submitted to the SMC
for reimbursement assessment, have on the ﬁnal recommenda-
tion decision by the SMC.Methods
A comprehensive database was created including information
from all drug appraisals performed by the SMC between January
2006 and July 2013. They year 2006 was chosen as the startingpoint for the SMC data collection for this analysis because this
year was considered to be the one in which SMC’s role was
strengthened and evolved into the one that it currently has [20].
The SMC publishes the reimbursement recommendation itself
together with wide-ranging details on the submission in a stand-
ardized format that is accessible to the general public [15].
Information from “full submissions” (i.e., submissions for the
ﬁrst time) as well as resubmissions was included in the database.
Appraisals that were labeled as “abbreviated submission” or “IRP
guidance (Independent Review Panel)” were not considered for
this research because they provided limited information on the
submitted evidence.
From each appraisal, numerous variables were extracted.
These included the opinion of the SMC (a product being accepted
for routine or for restricted use was treated as one category) and
several factors that were grouped into ﬁve main classes: clinical
evidence, therapeutic indication–related information, disease
characteristics, health economic evidence, and other relevant
information. Altogether, the data set included 20 variables that
were thought to potentially inﬂuence the recommendation of the
SMC. Table 1 presents these variables together with their deﬁ-
nitions and possible sets of values.
The extent to which the submitted evidence inﬂuences the
ﬁnal recommendation of the SMC was assessed by odds ratios
(ORs) estimated from binomial logistic regression analyses. The
STATA software was used [22]. Analyses took place in two
phases; in the ﬁrst phase, univariate logistic regression models
were set up to examine the relationship between each individual
independent variable (explanatory variables) and the decision of
the SMC (dependent variable), deﬁned as “to accept” or “not to
recommend” a product for use within NHS Scotland. In the
second phase, a multivariate logistic regression analysis was
undertaken to assess how the presence of multiple factors
inﬂuences the recommendation of the SMC. The explanatory
variables that indicated a statistically signiﬁcant relationship
with the dependent variable in univariate analyses (i.e., P r
0.05) were included in the multivariate model. If for a multi-
nomial explanatory variable at least one category was signiﬁ-
cantly associated with the outcome, then the whole multinomial
variable was considered for the multivariate analysis. Missing
information led to the exclusion of an observation from regres-
sion analyses.
Variable selection in the multivariate logistic regression
model was performed using a backward elimination procedure
[23]. Speciﬁcally, the backward elimination procedure started
with all considered variables (i.e., variables with a P value of
o0.05 in the univariate analysis), tested the deletion of each
variable for model improvement (exit criterion was a P value of
40.05), and repeated this process until no further improvement
was possible. The backward elimination algorithm was chosen
for this study because it is a commonly used and well-accepted
method for variable selection and because it is less adversely
affected by correlations among explanatory variables than are
other methods (e.g., forward selection and stepwise regression
methods) [23]. The predictive power of the multivariate model
was assessed by the area under the receiver operating
characteristic curve.
For the base-case analysis, resubmissions were treated as
original submissions. One could argue, however, that the result of
a resubmission was not independent from that of the original
submission because at the resubmission the manufacturer could
address the critique expressed by the SMC during the ﬁrst
assessment and could eventually increase the chance of a
positive recommendation. If this is true, depending on the
strength of this correlation and the number of resubmissions,
standard errors of the analyses may not be correct even though
parameter estimates would be still unbiased. To acknowledge
Table 1 – Description of variables included in the SMC data set.
Variable Deﬁnition Explanation
Clinical evidence
Type of compound D ¼ 0; Chemical
D ¼ 1; Biological
This variable indicated whether the entity of the drug is biological or chemical. Chemical entities contain an active
moiety (molecule or ion), whereas biological products are composed of cellular or tissue-based products (e.g.,
proteins, antibodies, and viruses).
Control arm in clinical
trial
D ¼ 0; Placebo
D ¼ 1; Active
D ¼ 2; Uncontrolled
This variable indicated the type of control arm used in the clinical trial that backed the
submitted clinical evidence in the submission. A trial could be active-controlled, placebo-controlled, or
uncontrolled (i.e., single-arm trial).
If more than one trial was reported, the one given as the pivotal trial was extracted and used. An
active-controlled trial was preferred over a placebo-controlled study in case more studies were reported and in case
none of them was marked as the pivotal one. If more than one active-controlled trial was reported, the one used in
the pharmacoeconomic analysis section of the SMC document was chosen to be extracted.
Clinical trial’s primary
end point
D ¼ 0; Lifesaving/hard end point
D ¼ 1; Surrogate end point
A trial was considered to have a potentially lifesaving/hard end point if the primary outcome
was to prevent an event (e.g., death or stroke). Surrogate end point has been deﬁned as “a biomarker intended to
substitute for a clinical end point” (e.g., lowering blood pressure).
The clinical primary end point of the chosen clinical trial, as described above “Control arm in
clinical trial,” was extracted and used.
Efﬁcacy proﬁle D ¼ 0; Trial was uncontrolled
D ¼ 1; Superior efﬁcacy vs. active
comparator
D ¼ 2; Superior efﬁcacy vs. placebo
D ¼ 3; Nonsuperior efﬁcacy vs. active
comparator
D ¼ 4; Nonsuperior efﬁcacy vs. placebo
A drug was considered to have superior/inferior efﬁcacy if the new drug was demonstrated to have a statistically
signiﬁcantly better/worse efﬁcacy proﬁle than the comparator regarding the primary trial end point. If the trial
was uncontrolled, no comparator was used.
Safety proﬁle D ¼ 0; Nonsuperior safety (similar safety)
D ¼ 1; Superior safety
D ¼ 2; Inferior safety
D ¼ 3; Trial was uncontrolled
A product was considered to have a superior/inferior safety proﬁle than its comparator if it was associated with
signiﬁcantly less/more severe adverse effects than its comparator. If the trial was uncontrolled, no comparator
was used.
Indication-related evidence
Therapy type D ¼ 0; Drugs meant for monotherapy
D ¼ 1; Drugs meant for combination
therapy
A new drug can be administered as a combination treatment, i.e., in combination with another drug, or as
monotherapy, i.e., administered alone.
Treatment line D ¼ 0; First-line treatment drug
D ¼ 1; Subsequent treatment line drug
A drug was considered to be a ﬁrst-line treatment if it was to be the ﬁrst treatment given to the patient after the
diagnosis. The drug was considered as later treatment line if it is indicated to be administered as a subsequent
treatment line, i.e., after the failure of the previous treatment option(s).
Chronic use D ¼ 0; Drug meant for chronic use
D ¼ 1; Drug not meant for chronic use
Chronic use indicated that a drug is indicated for the treatment of a chronic disease and no restrictions to the
treatment duration were deﬁned (i.e., treatment is administered until cure, discontinuation, or death). In contrast,
a product is not indicated for chronic use if it is indicated for the treatment of acute events or a deﬁnite treatment
duration is predeﬁned.
Competition D ¼ 0; Two or more competitors
D ¼ 1; One competitor
D ¼ 2; No competitors
No competitor in the market was considered if the drug of interest was to be the ﬁrst reimbursed treatment for the
speciﬁc indication. One or more competitors indicated if there were already one or more treatments reimbursed
for that indication.
Disease characteristics
Orphan indication D ¼ 0; Orphan indication
D ¼ 1; No orphan indication
Orphan indication was given to products that were recognized by the European Medicines Agency as orphan-
designated medicines to treat an orphan disease. An orphan (rare) disease affects a small percentage of the
population (about 5 in 10,000 people [21]).




























Table 1 – continued
Variable Deﬁnition Explanation
ATC code† Multiple categories; see below table for
all possible values
It was used to classify each product into the corresponding therapeutic area.
Childhood disease D ¼ 0; Not for children
D ¼ 1; For children
Health economic evidence
ICER as a result of the
economic analysis
performed
D ¼ 0; BC analysis demonstrates an ICER
below £30,000/QALY and SA an ICER
above £30,000/QALY
D ¼ 1; BC and SA demonstrate an ICER
below £30,000/QALY
D ¼ 2; BC and SA demonstrate an ICER
above £30,000/QALY gained
D ¼ 3; ICER is negative due to negative
costs and QALY gain
D ¼ 4; A cost-minimization analysis is
performed
This variable indicated the type of economic analysis performed and backed the submission.
CEA and CUA are economic analyses in which the incremental cost per QALY is calculated. The ICER is an outcome
of a CEA/CUA. Results of both the base-case economic analysis and the analysis around uncertainty were recorded
to analyze the ICER level and whether the ICER exceeded the predeﬁned threshold of £30,000/QALY gained. The
SMC does not have a formal ICER threshold; hence, the ofﬁcial NICE threshold was assumed to represent the value
upon which a technology is deemed to be cost-effective by the SMC. A cost-minimization analysis assumes similar
efﬁcacy and is used to show the difference in cost implications of two or more alternative treatment options.
If a range of base-case ICERs was reported because multiple analyses were conducted for different drug comparators,
the ICER of an analysis based on an active-controlled trial was preferred to be extracted over the ICER of an analysis
based on a placebo-controlled trial. If more than one ICER was reported for the same analysis/comparator as the
submission dossier may cover more than one population, we conservatively extracted the higher reported one.
Budget impact at year 5 D ¼ 0; Budget impact at year 5 is not
mentioned
D ¼ 1; Estimated net budget impact at
year 5 is over £500,000
D ¼ 2; Estimated net budget impact at
year 5 is below £500,000
The manufacturer is requested to estimate and submit a budgetary impact of introducing a new product into the




D ¼ 0; Not mentioned
D ¼ 1; Underestimated
D ¼ 2; Overestimated
This variable indicated whether the SMC stated that the budget impact was overestimated or underestimated. The
“not mentioned; no report of the SMC on whether the budget impact was over- or underestimated” was set as the
reference case.
Other information
Company size D ¼ 0; Manufacturer submitting the drug
is a small company
D ¼ 1; Manufacturer submitting the drug
is a big company
The manufacturer’s company size was deﬁned as big/small, as sorted on the basis of their total revenues.
Companies with total revenues of Z1.5 billion* were considered as big size companies, whereas ﬁrms with total
revenues below this cutoff point were considered as small size companies.
Year of submission 2006, 2007, …, 2013 The year when the SMC decision upon recommendation was issued.
Patient interest group
presence
D ¼ 0; No patient interest group attached
comments to submission
D ¼ 1; A patient interest group attached
comments to submission
Patient interest groups are able to collate comments from a number of patients and carers and provide these in the
form of a submission of evidence to the SMC as part of the manufacturer’s submission.
Resubmission D ¼ 0; Submission for the ﬁrst time
D ¼ 1; Submission for at least the
second time
This variable indicated whether the submission under analysis is a resubmission. Where there is signiﬁcant new
information about a drug, or new analysis of existing information, the sponsor company may make a
resubmission, which is essentially a complete de novo assessment through usual SMC processes. This type of
submission is usually after the SMC had already rejected to recommend the product of interest at least once.
Note: D ¼ 0 was treated as reference category in logistic regression analyses.
ATC, Anatomical Therapeutic Chemical (ATC) Classiﬁcation System; BC, base case; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; ICER, incremental cost-effectiveness ratio; NICE,
National Institute for Health and Care Excellence; QALY, quality-adjusted life-year; SA, sensitivity analysis; SMC, Scottish Medicines Consortium.
* As sorted and presented in “Fortune Global 500 2009 Pharmaceutical Industry” and “Global 500.” CNN. 2008.
† ATC codes: A, alimentary tract and metabolism; B, blood and blood-forming organs; C, cardiovascular system; D, dermatologicals; G, genitourinary system and sex hormones; H, systemic
hormonal preparations, excluding sex hormones and insulins; J, antiinfectives for systemic use; L, antineoplastic and immunomodulating agents; M, musculoskeletal system; N, nervous




























V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 8 4 – 2 9 1288this potential limitation, a sensitivity analysis was conducted
excluding the subset of resubmissions and its impact on the
standard error of the parameter estimates was observed.Results
A total of 463 appraisal documents (full submissions and resub-
missions) published on the SMCWeb site between January 2006 and
July 2013 were reviewed and extracted. Of the 463 submissions, 265
(57%) were accepted for use and 198 (43%) were not recommended
for use within NHS Scotland. Of the ones that received a positive
opinion, 150 (57%) were accepted for restricted use, for example, for
a limited patient population or for a restricted time period, while
115 submissions were accepted for routine use.
Base Case
Table 2 provides an overview of results of univariate analyses
including the estimated OR, the probability of positive recom-
mendation, and the number of submissions for each variable and
category within a variable. An OR above 1 indicated higher odds
of a positive recommendation than rejection. In total, 13 factors
demonstrated a signiﬁcant association with reimbursement rec-
ommendation by the SMC (these are marked with an asterisk in
Table 2). Of these, 8 factors were related to clinical evidence,
indication, and disease characteristics, while 5 factors were
associated with economic evidence and size of the manufac-
turer’s company.
Economic evidence seemed to be strongly inﬂuential for the
reimbursement recommendation. Submissions supported by a
cost-minimization analysis had higher odds of receiving a pos-
itive recommendation (OR ¼ 8.3; 95% conﬁdence interval [CI] 3.9–
17.6) than did submissions supported by a not robust cost-utility
analysis (base-case ICER below £30,000/QALY and sensitivity
analyses above £30,000/QALY). Similarly, economic evidence
showing that the new treatment dominates the comparator
treatment (i.e., demonstrating cost savings and yielding addi-
tional QALYs) was associated with high odds of a positive
recommendation (OR ¼ 6.4; 95% CI 2.2–18.9).
Moreover, it was shown that an active controlled trial (OR ¼
2.08; 95% CI 1.41–3.07) is preferred over a placebo or an uncon-
trolled one. A surprising observation was that submissions based
on nonsuperior efﬁcacy results against an active comparator,
however, had a signiﬁcant and higher OR than did submissions
based on superior efﬁcacy results against an active comparator
when compared with uncontrolled trials. This is likely explained,
however, by insufﬁcient power.
Variables that demonstrated a statistically signiﬁcant associ-
ation with the SMC recommendation in univariate analyses were
included in the multivariate regression model and were subject
to the variable selection procedure. The backward elimination
process resulted in a ﬁnal multivariate model including seven
factors. Four of these were related to health economic evidence,
while three were associated with therapeutic indication, disease
characteristics, and manufacturer’s company size. Results of the
multivariate analysis (OR and the P values) are presented in
Table 3.
Several of the variables that were signiﬁcant in univariate
analyses were eliminated in multivariate analyses because the
variance they explained was shared with stronger predictive
variables. For instance, an orphan product, which was shown to
have a signiﬁcant impact on the univariate analysis, was not an
explanatory variable in the multivariate analysis. The reason is
that submissions concerning orphan products demonstrated a
high ICER; hence, the ICER is a stronger explanatory variable that
eventually remains in the analysis.The area under the receiver operating characteristic curve of
the ﬁnal multivariate model was estimated to be 0.80, indicating
that the prediction accuracy of the developed model was reason-
ably high; that is, the model was able to predict the SMC
decisions correctly in 80% of the cases.
Sensitivity Analysis
The sensitivity analysis, in which applications submitted only once
were included in the data set, revealed the same factors to
inﬂuence the recommendation decision by the SMC. The OR and
CIs are similar to the ones from the base case, demonstrating the
robustness of the results. Besides, the data set consisted of a small
number of resubmissions (115 resubmissions; 25%), which was
considered unlikely to introduce any bias in the base-case analysis.Conclusions
The purpose of the present study was to investigate the weight
the different components of evidence, submitted to the SMC for
reimbursement, have on the ﬁnal recommendation decision.
Out of the 463 submissions that were included in the analyses,
265 were accepted for use (57%) and 198 (43%) were not recom-
mended for use within NHS Scotland. Univariate analyses showed
that 13 variables signiﬁcantly affected the SMC decision. Of these 13
variables, 7 variables were shown to have a meaningful impact in
the multivariate analysis. Four of these concerned the outcome of
the cost-effectiveness analyses; the fact that a submission was
supported by a cost-minimization analysis was the strongest
positive variable (OR ¼ 10.3) and a submission showing a product
not being cost-effective (i.e., an ICER above £30,000/QALY) was the
strongest negative predictor (OR ¼ 0.47). The other variables con-
cerned whether the submission was related to a product indicated
for a nervous system disease (OR ¼ 0.41), whether it was indicated
for nonchronic use (OR ¼ 1.66), and whether the submission was
performed by a big company (OR ¼ 2.83).
Other authors have investigated similar research questions but
for other countries. For England andWales, Dakin et al. [6] found that
the most inﬂuential factors affecting recommendations were the
number of randomized clinical trials, inclusion of cost-utility analysis
in submission, the ICER, and whether the product of interest was a
lifesaving intervention. Devlin and Parkin [7] also found that the ICER
had the most inﬂuential impact on NICE decisions. The results by
Cerri et al. [10] indicated that the following factors were important:
demonstration of statistical superiority, the ICER, the number of
pharmaceuticals appraised within the same appraisal, and the
appraisal year. Harris et al. [12] found that clinical signiﬁcance,
cost-effectiveness, budget impact, and disease severity were the
most inﬂuential factors for a positive coverage decision for Australia.
In The Netherlands, Cerri et al. [11] found the following factors to
signiﬁcantly affect the reimbursement decision of the Dutch national
health authority: active comparator of the pivotal trial, the budget
impact, the therapeutic indication, and the target population.
The ﬁndings of these studies are difﬁcult to be compared
because of differences in reimbursement systems, methodologies
applied, and sample of reimbursement cases studied. A common
ﬁnding in Scotland, England and Wales, and Australia, however,
was that the ICER is an important criterion for the reimburse-
ment decision [6,7,10,12], surprisingly not in The Netherlands
[11]. Other factors that were of signiﬁcant impact in our analyses,
for example, the size of the company and whether the products
are indicated for nonchronic use, were not included and analyzed
in the other before-mentioned analyses. The therapeutic indica-
tion and disease severity were inﬂuential in our analyses for
Scotland and in The Netherlands and in Australia [11,12], but not
in England and Wales [6,7,10].
Table 2 – Results of univariate logistic regression analyses.









Type of compound, biological Type of compound,
chemical
1.11 (0.73–1.71) 0.619 52.61 120 (26)
Active comparator* Placebo arm 2.08 (1.41–3.07) 0.000* 67.53 205 (44)
Uncontrolled 0.81 (0.36–1.80) 0.600 44.75 27 (6)
Nonsuperior efﬁcacy vs. active
comparator*
Uncontrolled trial 3.05 (1.29–7.19) 0.011* 75.31 117 (25)
Superior efﬁcacy vs. active comparator 2.08 (0.87–4.99) 0.099 67.53 88 (19)
Superior efﬁcacy vs. placebo 1.27 (0.57–2.84) 0.556 55.95 224 (48)
Nonsuperior efﬁcacy vs. placebo 0.50 (0.08–3.05) 0.452 33.33 7 (2)
Superior safety Nonsuperior safety 2.05 (0.88–4.79) 0.096 67.21 30 (6)
Inferior safety proﬁle 0.96 (0.64–1.44) 0.850 48.98 151 (33)
Uncontrolled trial 0.25 (0.05–1.26) 0.092 37.50 27 (6)
Type trial’s primary end point,
surrogate end point
Type trial’s primary
end point, hard end
point
1.42 (0.95–2.13) 0.084 58.68 326 (70)
Indication-related evidence
Given in combination Given as
monotherapy
0.97 (0.65–1.42) 0.865 49.24 164 (35)
First-line treatment Other treatment lines 1.17 (0.81–1.70) 0.395 53.92 214 (46)
Product indicated for nonchronic use* Indicated for chronic
use
1.79 (1.21–2.67) 0.003* 64.16 166 (36)
Competition, available treatments ¼ 1 Competition, two or
more available
treatments
1.18 (0.65–2.14) 0.586 54.13 352 (76)
Competition, no available treatment 0.60 (0.37–1.05) 0.076 37.50 55 (12)
Disease characteristics
No orphan indication* Orphan indication 2.15 (1.25–3.70) 0.006* 68.25 398 (86)
Childhood disease Not indicated for
children
1.15 (0.71–1.85) 0.573 53.49 91 (20)
ATC code
ATC A (alimentary tract and
metabolism)
ATC B–V 1.61 (0.85–3.08) 0.145 61.69 46 (10)
ATC B (blood and blood-forming organs)* ATC A, C–V 4.37 (1.66–11.54) 0.003* 81.38 34 (7)
ATC C (cardiovascular system)* ATC A, B, D–V 0.41 (0.17–0.99) 0.049* 29.08 22 (5)
ATC D (dermatologicals) ATC A–C, G–V 1.32 (0.38–4.56) 0.665 56.90 11 (2)
ATC G (genitourinary system and sex
hormones)
ATC A–D, H–V 2.10 (0.66–4.56) 0.210 67.74 15 (3)
ATC H (systemic hormonal
preparations, excluding sex
hormones and insulins)
ATC A–G, J–V 0.49 (0.14–1.76) 0.275 32.89 10 (2)
ATC J (antiinfectives for systemic use)* ATC A–H, L–V 4.82 (1.99–11.69) 0.001* 82.82 42 (9)
ATC L (antineoplastic and
immunomodulating agents)*
ATC A–J, M–V 0.63 (0.42–0.94) 0.022* 38.65 151 (33)
ATC M (musculoskeletal system) ATC A–L, N–V 1.23 (0.50–3.02) 0.658 55.16 21 (5)
ATC N (nervous system)* ATC A–M, R–V 0.57 (0.34–0.95) 0.033* 36.31 68 (15)
ATC R (respiratory system) ATC A–N, S–V 0.58 (0.27–1.51) 0.268 36.71 18 (4)
ATC S (sensory organs) ATC A–R, V 1.20 (0.39–3.73) 0.751 54.55 13 (3)
ATC V (various) ATC A–S 0.36 (0.11–1.23) 0.103 26.47 12 (3)
Economic evidence
Cost-minimization analysis performed* BC below 30, SA above
30
8.29 (3.91–17.58) 0.000* 89.24 94 (20)
Cost savings and QALY gain* 6.44 (2.19–18.86) 0.001* 86.56 28 (6)
ICER below £30,000 (both BC and SA)* 2.96 (1.64–5.36) 0.000* 74.75 105 (23)
ICER above £30,000 (both BC and SA) 0.57 (0.31–1.09) 0.096 36.31 134 (29)
BI year 5 o£500,000 BI not known 1.46 (0.94–2.26) 0.092 59.32 211 (46)
BI year 5 4£500,000 0.81 (0.49–1.33) 0.404 44.73 116 (25)
BI overestimating BI no mention
overestimation/
underestimation
1.51 (0.91–2.52) 0.110 60.22 83 (18)
BI underestimating 0.79 (0.48–1.30) 0.353 44.14 79 (17)
continued on next page
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Table 2 – continued









Big company* Small company 2.04 (1.36–3.05) 0.001* 67.11 325 (70)
Resubmission Full submission 0.80 (0.52–1.22) 0.295 44.44 115 (25)
Patient interest group presence No presence 0.84 (0.58–1.21) 0.341 45.65 222 (48)
Year of submission
2006 2007–2013 0.77 (0.47–1.31) 0.358 43.50 69 (15)
2007 2006, 2008–2013 0.80 (0.47–1.36) 0.403 44.44 63 (14)
2008 2006, 2007, 2009–2013 1.09 (0.64–1.86) 0.742 52.15 66 (14)
2009 2006–2008, 2010–2013 1.41 (0.77–2.57) 0.269 58.51 52 (11)
2010 2006–2009, 2011–2013 1.47 (0.81–2.69) 0.209 59.51 68(15)
2011 2006–2010, 2012, 2013 0.76 (0.45–1.28) 0.299 43.18 61 (13)
2012 2006–2011, 2013 1.01 (0.58–1.74) 0.981 50.25 54 (12)
2013 2006–2012 1.31 (0.73–2.35) 0.366 56.71 30 (6)
ATC, Anatomical Therapeutic Chemical (ATC) Classiﬁcation System; BC, base case; BI, budget impact; CI, conﬁdence interval; ICER,
incremental cost-effectiveness ratio; SA, sensitivity analysis.
* Signiﬁcant impact has been shown.









Cost savings and QALY gain 8.91 (2.84–27.89) 0.000
ICER below £30,000/QALY (both
BC and SA)
3.08 (1.64–5.77) 0.000








ATC N: Nervous system* 0.41 (0.21–0.79) 0.009
Other
Big company 2.83 (1.68–4.79) 0.000
ATC, Anatomical Therapeutic Chemical (ATC) Classiﬁcation Sys-
tem; BC, base case; CI, conﬁdence interval; ICER, incremental cost-
effectiveness ratio; SA, sensitivity analysis; QALY, quality-adjusted
life-year.
* Examples related to products indicated for nonchronic use:
product indicated for treatment of major depressive episodes or
for manic episodes associated with bipolar I disorder; Example
for ATC N (nervous system) products: product indicated for
invasive candidiasis or for topical treatment of moderate scalp
psoriasis.
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The results of this study present (at least) three important
implications for future reimbursement submissions. First, our
analyses suggest that the ICER and the uncertainty around the
ICER are signiﬁcant factors for a successful reimbursement
submission in the SMC. Consequently, the pricing of the product
(including orphan-designated products) should be carefully con-
sidered by the manufacturer on the grounds of the implications
that the price may have on the reimbursement recommendations
of its product [24].
A cost-minimization analysis assumes similar efﬁcacy and is
used to show the difference in cost implications of two or more
alternative treatment options [25]. The fact that a performance of
cost-minimization analyses was associated with a high proba-
bility of positive recommendation suggests that the SMC may
prefer a case that can be backed up by a simple pharmacoeco-
nomic analysis, such as a cost-minimization one.
Furthermore, it was shown that the trial design is taken into
consideration by the SMC. An active-controlled trial is preferred
over the placebo one. Therefore, manufacturers should take this
into consideration trying to fulﬁll the reimbursement require-
ments along with the marketing authorization needs because
this tends to be a hurdle for a product’s introduction in the
market.
Another interesting insight was drawn from the multivariate
analysis, which revealed that an application submitted by one of
the big pharmaceutical companies had a higher chance of being
accepted for use than did an application submitted by a small
company. This is likely explained by the fact that big companies
have more experience and fund available for conducting the right
trials and for building the economic evidence that is needed for
SMC submissions. Hence, appropriate funding for high-quality
trials and evidence is a necessary tool along the process of a
product’s development.
Finally, this research makes the importance or weight of
different variables (e.g., clinical, health economic, and burden
of illness) on the reimbursement recommendation in Scotland
transparent. This is relevant for the understanding of all
stakeholders of the Scottish reimbursement process (e.g.,
SMC, manufacturers, patient interest groups, and clinicians).
For manufacturers and lobbying organizations, it could help to
further improve their reimbursement submissions and claimsregarding their products. Moreover, this transparency can be
used, if deemed necessary, for further reﬁnement of the
current reimbursement process and criteria. For instance, it
is important to mention that patient interest groups have
already moved forward into ﬂagging their difﬁculty in accept-
ing the importance of the ICER to the SMC committee and their
concerns about the implications on the access of patients to
certain effective medicines [26]. Consequently, SMC is
requested to introduce a new, more ﬂexible decision-making
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orphan medicines, and ultraorphan medicines that is not
based on cost-effectiveness outcomes [26]. It will be interest-
ing to observe in a future research the consequences of this
new approach (when available and implemented) for the
assessment process and acceptance rates for these products.Limitations
Findings of this study should be interpreted with the following
limitations. First, no variables related to the decision process (e.g.,
policy changes, size of the committee, members, and expertise)
were considered in the analyses. Second, the ICER threshold of
£30,000/QALY was used in analyses because it is evidently
reported in SMC appraisal decisions as an evidence that is taken
into consideration. Yet, the SMC does not have a formal ICER
threshold; hence, this value, being the ofﬁcial threshold applied
by NICE, was assumed to represent the value upon which a
technology is deemed to be cost-effective by the SMC. The
arbitrarily chosen thresholds for the ICER (e.g., £30,000/QALY
gained) and the budget impact (e.g., £500,000 in year 5) could
have affected the results. Furthermore, it should be noted that
even though the SMC assessment does not go beyond the
company’s submission, it might estimate its own unofﬁcial ICER
to support its decision [14,16]. This analysis, however, was
dependent on publicly available information, and it was assumed
that the base case published by the SMC is the one on which the
ﬁnal recommendation was based.
Finally, in our study, a positive recommendation was deﬁned as a
product being accepted for use with or without any restrictions.
For this study, we did not pursue to separate the full acceptance
for use from an acceptance for restricted use because the total
number of submissions per level of recommendation would have
been too low to draw robust conclusions. In addition, it is
unknown whether it was the manufacturer’s strategic decision
to request reimbursement recommendation with restrictions, or
it was the SMC who came to this conclusion given the submitted
evidence. Therefore, it cannot be assumed that a restricted
acceptance represents a lesser favorable decision because this
may serve, for example, the therapeutic indication of the product
of interest. Nonetheless, it is acknowledged that future research
could take into account the multinomial nature of the recom-
mendation outcome.
The SMC database that was created for this analysis is
assessed to be comprehensive, including information from all
different components of submitted evidence. In addition, the
sample for this analysis is the biggest that has been created for
this type of analysis and it is the only one related to the SMC
coverage recommendations. Future research could include a
consistent assessment of cases and explanatory variables and
methodologies across countries to better understand and explain
differences across different health care systems.
To conclude, the present study identiﬁed the most inﬂuential
factors to the reimbursement recommendation by the SMC. It
was shown that favorable ICER (i.e., base-case ICER and sensi-
tivity analysis around it below £30,000/QALY gained) is crucial for
a successful submission. Both univariate and multivariate anal-
yses showed that this comes in combination with the clinical
evidence, the target disease, and the company’s size, which also
play a signiﬁcant role in SMC reimbursement decisions. It is
interesting to observe that these conclusions are in line with the
publicly stated objective of the SMC: “Will the medicine be
effective? Are current treatments better? Does the medicine give
value for money compared to existing treatments? These are the
main questions asked while considering new medicines’ appro-
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